William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working against Charles River in the near term to make the stock ...

In Upslope’s view, CRL is a cyclical compounder going through a…cyclical downturn. Why are we bullish CRL stock? Click here ...

Shares for Charles River Laboratories slipped after the company said it expects revenue to decline in 2025. Shares of the Massachusetts-based pharmaceutical company were recently down 6% to $178.50 in ...

At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Apollo for Biologics: Provides a centralized platform to submit sample submission forms, track samples, and exchange documents all in one place, ensuring accuracy and saving time.